Therapeutics Advances
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Nephrol. Jul 6, 2016; 5(4): 300-307
Published online Jul 6, 2016. doi: 10.5527/wjn.v5.i4.300
Update on kidney transplantation in human immunodeficiency virus infected recipients
Khaled Nashar, Kalathil K Sureshkumar
Khaled Nashar, Kalathil K Sureshkumar, Division of Nephrology and Hypertension, Department of Medicine, Allegheny General Hospital, Pittsburgh, PA 15212, United States
Author contributions: Both authors contributed to literature search, writing of the manuscript.
Conflict-of-interest statement: None.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Kalathil K Sureshkumar, MD, FRCP (Glasgow), FASN, Division of Nephrology and Hypertension, Department of Medicine, Allegheny General Hospital, 320 East North Avenue, Pittsburgh, PA 15212, United States. ksureshk@wpahs.org
Telephone: +1-412-3593319 Fax: +1-412-3594136
Received: February 24, 2016
Peer-review started: February 26, 2016
First decision: March 24, 2016
Revised: April 10, 2016
Accepted: May 7, 2016
Article in press: May 9, 2016
Published online: July 6, 2016
Processing time: 125 Days and 23.5 Hours
Abstract

Improved survival of human immunodeficiency virus (HIV) infected patients with chronic kidney disease following the introduction of antiretroviral therapy resulted in the need to revisit the topic of kidney transplantation in these patients. Large cohort studies have demonstrated favorable outcomes and proved that transplantation is a viable therapeutic option. However, HIV-infected recipients had higher rates of rejection. Immunosuppressive therapy did not negatively impact the course of HIV infection. Some of the immunosuppressive drugs used following transplantation exhibit antiretroviral effects. A close collaboration between infectious disease specialists and transplant professionals is mandatory in order to optimize transplantation outcomes in these patients. Transplantation from HIV+ donors to HIV+ recipients has been a subject of intense debate. The HIV Organ Policy Equity act provided a platform to research this area further and to develop guidelines. The first HIV+ to HIV+ kidney transplant in the United States and the first HIV+ to HIV+ liver transplant in the world were recently performed at the Johns Hopkins University Medical Center.

Keywords: End-stage kidney disease; Human immunodeficiency virus; Antiretroviral therapy; Kidney transplantation

Core tip: Experience with kidney transplantation in human immunodeficiency virus (HIV) positive patients is evolving. With appropriate selection of candidates, the outcomes appear similar to that in HIV negative population. There are challenges with kidney transplantation in HIV positive patients including increased risk for acute rejection and drug-drug interactions. Optimal immunosuppressive regimen is unknown. This article discusses the recent advances in kidney transplantation among HIV positive patients.